clinical trial · NCT07243275
SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease
Indiana University·phase4·recruiting·n = 260
Dry Eye Disease (DED)SYSTANE® PROMIEBO™ (Perfluorohexyloctane, PFHO)
brief summary
This is a prospective, randomized, double-masked, multi-site clinical trial designed to compare the efficacy of SYSTANE® PRO (Alcon Laboratories, Inc.) to MIEBO™ (Bausch + Lomb) in treating symptoms of evaporative dry eye disease (DED). The primary goal is to determine whether SYSTANE® PRO is non-inferior to MIEBO™ after one month of treatment, based on change in Ocular Surface Disease Index (OSDI) scores.
started
Feb 18, 2026
primary completion
Sep 30, 2026
completion
Sep 30, 2026
last updated
Mar 27, 2026
official title
Comparing the Efficacy of SYSTANE® PRO to MIEBO™ for the Treatment of Dry Eye Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol